These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21074215)

  • 1. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy.
    Wibowo E; Schellhammer P; Wassersug RJ
    J Urol; 2011 Jan; 185(1):17-23. PubMed ID: 21074215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.
    Freedland SJ; Eastham J; Shore N
    Prostate Cancer Prostatic Dis; 2009; 12(4):333-8. PubMed ID: 19901933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hormone therapy for prostate cancer].
    Théodore C
    Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hormonal treatments of prostate cancer].
    Kuhn JM
    Rev Prat; 1990 Nov; 40(25):2357-62. PubMed ID: 2124721
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hormonotherapy for prostate cancer].
    Oishi K; Yoshida O
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2300-5. PubMed ID: 8259842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine therapy for prostate cancer.
    Damber JE
    Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine therapy for prostate cancer.
    Sagalowsky AI
    Spec Top Endocrinol Metab; 1985; 7():101-29. PubMed ID: 3914094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy.
    Nishiyama T; Kanazawa S; Watanabe R; Terunuma M; Takahashi K
    Int J Urol; 2004 Sep; 11(9):735-41. PubMed ID: 15379937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy.
    Kruithof-Dekker IG; Têtu B; Janssen PJ; Van der Kwast TH
    J Urol; 1996 Sep; 156(3):1194-7. PubMed ID: 8709345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR
    Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating prostate cancer. Part V: androgen deprivation and chemotherapy.
    Harv Mens Health Watch; 1999 Dec; 4(5):5-8. PubMed ID: 10564905
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of advanced prostate cancer.
    Lynch JH
    J Fam Pract; 1993 Nov; 37(5):488-94. PubMed ID: 7693859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms.
    Schally AV; Redding TW; Comaru-Schally AM
    Cancer Treat Rep; 1984 Jan; 68(1):281-9. PubMed ID: 6362868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.